Entering text into the input field will update the search result below

BioMarin: Keep Waiting For The Growth

Mar. 03, 2022 4:43 PM ETBioMarin Pharmaceutical Inc. (BMRN)9 Comments
Denis Buivolov, CFA profile picture
Denis Buivolov, CFA


  • BioMarin released positive financials, but investors were disappointed by some clinical trial data.
  • Voxzogo: positive start to sales, but negative data from trials in children under five years old.
  • ValRox: waiting for the EU approval.

Штаб-квартира BioMarin в Силиконовой долине

Sundry Photography/iStock Editorial via Getty Images


In my previous articles, I highlighted the undervaluation of BioMarin's (NASDAQ:BMRN) shares. Nevertheless, after the last report, the company's shares fell. In this article, I would like to analyze the reasons for the fall of the

This article was written by

Denis Buivolov, CFA profile picture
I am global equity research analyst at investment company with the specializaton in Biotechnology, Internet and Media. Received my CFA Charter in 2017. Also, I have passed two level of the FRM exam.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BMRN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This is not investment advice. I am not an investment adviser. Before making any investment, please do your own research!

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.